Skip to content

Immunity of the Vaccine against Yellow Fever in patients taking medications that affect the immune system

Yellow Fever Vaccine immunity in patients using immunomodulatory therapies

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-946bv5
Enrollment
Unknown
Registered
2018-05-18
Start date
2014-09-17
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unspecified rheumatoid arthritis

Interventions

A cross-sectional observational study in which 150 patients diagnosed with rheumatoid arthritis who had previously received the yellow fever vaccine will be submitted to blood collection for neutraliz
Other
E01.370.225.500.363.342

Sponsors

Centro de Pesquisas René Rachou- FIOCRUZ
Lead Sponsor
Centro de Pesquisas René Rachou- FIOCRUZ
Collaborator

Eligibility

Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Be over 18 years of age; to present a diagnosis of Rheumatoid Arthritis; being in use of immunosuppressants; be accompanied at the University Hospital of Brasília; have previously been vaccinated against yellow fever

Exclusion criteria

Exclusion criteria: Pregnant women ; organic mental illness; carriers of other autoimmune diseases or neoplasms

Design outcomes

Primary

MeasureTime frame
Expected outcome 1: A lower vaccine protection in the study group (rheumatoid arthritis using immunosuppressants) was verified by the antigen-specific B and T lymphocyte profile, analyzed by flow cytometry of the peripheral mononuclear cell culture;Expected outcome 2: The study group (rheumatoid arthritis using immunosuppressants) has a lower amount of neutralizing antibodies, verified by the PRNT (plaque reduction neutralization test) method, in comparison to the control group

Secondary

MeasureTime frame
Less vaccine protection in the study group (rheumatoid arthritis using immunosuppressive drugs) verified by the signature profile of intracytoplasmic cytokines, analyzed by flow cytometry of the peripheral mononuclear cell culture

Countries

Brazil

Contacts

Public ContactClarissa ;Clarissa Ferreira;Ferreira

Hospital Universitário de Brasilia;Hospital Universitário de Brasilia

ferreira.clarissa@gmail.com;ferreira.clarissa@gmal.com+55-061-20285000;55 061 20285000

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Mar 3, 2026